^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

DCVax-L (autologous dendritic cell vaccine leaded with autologous tumor cell lysate)

i
Other names: DCVac-L, DCVax-Brain, DCVax-Ovarian
Associations
Company:
Northwest Biotherap
Drug class:
Immunostimulant
Related drugs:
Associations
1year
Multiphase combined treatment, including individualized multimodal immunotherapy for adults with GBM: single institute real world medical data in the light of clinical trial research data (SNO 2023)
We designed a multiphase combined treatment using subsequentially 1/ modulated electrohyperthermia and Newcastle Disease Virus therapy to induce immunogenic cell death (ICD) during temozolomide maintenance chemotherapy, 2/ two autologous DC vaccinations (IO-Vac®), and 3/ ICD immunotherapy, long-peptide vaccines and one boost IO-Vac® vaccine. TTF improved the OS in both unmeth and meth patients (17m/27% and 32m/59%), while DCvax®-L improved OS only in meth patients (15m/19% and 30m/58%). These real world data support to prospectively explore the addition of individualized multimodal immunotherapy during and after standard of care, and the role of treatment adaptations during treatment.
Clinical • Real-world evidence • PD(L)-1 Biomarker • IO biomarker • Real-world
|
PD-L1 (Programmed death ligand 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
PD-L1 expression • IDH wild-type
|
temozolomide • DCVax-L (autologous dendritic cell vaccine leaded with autologous tumor cell lysate)
over1year
DCVax-L Vaccination in Patients with Glioblastoma: Real Promise or Negative Trial? The Debate Is Open. (PubMed, Cancers (Basel))
The results of the phase III clinical trial of DCVax-L (autologous tumor lysate-loaded dendritic cell vaccination), which has been shown to increase both median survival and long-term survival in newly diagnosed and relapsed glioblastoma, have been enthusiastically received by the scientific community. However, this study deserves some reflections regarding methodological issues related to the primary endpoint change, the long accrual period, and the suboptimal validity of the external control population used as the comparison arm.
Journal
|
DCVax-L (autologous dendritic cell vaccine leaded with autologous tumor cell lysate)
over1year
Assessment of treatment response to dendritic cell vaccine in patients with glioblastoma using a multiparametric MRI-based prediction model. (PubMed, J Neurooncol)
Multiparametric MRI-based prediction model can assess treatment response to DCVax-L in patients with glioblastoma.
Journal
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
MGMT promoter methylation
|
DCVax-L (autologous dendritic cell vaccine leaded with autologous tumor cell lysate)
over1year
Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma: What happened to the evidence? (PubMed, Rev Neurol (Paris))
Dendritic cell vaccination remains a promising approach for GBM. It is therefore disappointing that due to key methodological limitations, the DCVax-L trial ultimately failed to provide sound conclusions about the potential efficacy of such approach for patients with glioblastoma.
Review • Journal
|
DCVax-L (autologous dendritic cell vaccine leaded with autologous tumor cell lysate)